Appili Therapeutics Inc. (APLI.TO)
CAD 0.04
(-12.5%)
CAD 0.04
(-12.5%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.78 Million CAD | 59.09% |
| 2022 | -9.24 Million CAD | 63.2% |
| 2021 | -25.11 Million CAD | -75.34% |
| 2020 | -14.32 Million CAD | -164.47% |
| 2019 | -5.41 Million CAD | -25.06% |
| 2018 | -4.33 Million CAD | -8.93% |
| 2017 | -3.97 Million CAD | -126.65% |
| 2016 | -1.75 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.58 Million CAD | -43.63% |
| 2023 Q4 | -1.1 Million CAD | -624.36% |
| 2023 FY | -3.78 Million CAD | 59.09% |
| 2023 Q3 | -152.33 Thousand CAD | 84.4% |
| 2023 Q2 | -976.55 Thousand CAD | 36.94% |
| 2023 Q1 | -1.54 Million CAD | 41.8% |
| 2022 Q1 | -2.32 Million CAD | 30.26% |
| 2022 Q4 | -2.66 Million CAD | -1.57% |
| 2022 FY | -9.24 Million CAD | 63.2% |
| 2022 Q3 | -2.61 Million CAD | -59.89% |
| 2022 Q2 | -1.63 Million CAD | 29.53% |
| 2021 Q3 | -3.23 Million CAD | 71.02% |
| 2021 FY | -25.11 Million CAD | -75.34% |
| 2021 Q1 | -7.36 Million CAD | -47.82% |
| 2021 Q2 | -11.17 Million CAD | -51.67% |
| 2021 Q4 | -3.33 Million CAD | -2.91% |
| 2020 FY | -14.32 Million CAD | -164.47% |
| 2020 Q1 | -2.59 Million CAD | -101.86% |
| 2020 Q4 | -4.98 Million CAD | -16.85% |
| 2020 Q3 | -4.26 Million CAD | -72.34% |
| 2020 Q2 | -2.47 Million CAD | 4.72% |
| 2019 Q3 | -1.18 Million CAD | -2.68% |
| 2019 Q2 | -1.14 Million CAD | 36.09% |
| 2019 Q1 | -1.79 Million CAD | -37.7% |
| 2019 FY | -5.41 Million CAD | -25.06% |
| 2019 Q4 | -1.28 Million CAD | -9.02% |
| 2018 FY | -4.33 Million CAD | -8.93% |
| 2018 Q4 | -1.3 Million CAD | -8.16% |
| 2018 Q1 | -483.76 Thousand CAD | 65.78% |
| 2018 Q2 | -1.33 Million CAD | -175.51% |
| 2018 Q3 | -1.2 Million CAD | 9.37% |
| 2017 FY | -3.97 Million CAD | -126.65% |
| 2017 Q4 | -1.41 Million CAD | -38.72% |
| 2017 Q3 | -1.01 Million CAD | 0.0% |
| 2016 FY | -1.75 Million CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Eupraxia Pharmaceuticals Inc. | -37.39 Million CAD | 89.888% |
| Helix BioPharma Corp. | -9.26 Million CAD | 59.187% |
| Microbix Biosystems Inc. | -39.48 Thousand CAD | -9476.045% |
| Medicenna Therapeutics Corp. | -25.46 Million CAD | 85.153% |
| Satellos Bioscience Inc. | -15.88 Million CAD | 76.204% |
| Oncolytics Biotech Inc. | -27.75 Million CAD | 86.376% |
| Sernova Corp. | -38.99 Million CAD | 90.305% |